Engineering functional inorganic-organic hybrid systems: Advances in siRNA therapeutics

Jianliang Shen, Wei Zhang, Ruogu Qi, Zong Wan Mao, Haifa Shen

Research output: Contribution to journalReview articlepeer-review

122 Scopus citations

Abstract

Cancer treatment still faces a lot of obstacles such as tumor heterogeneity, drug resistance and systemic toxicities. Beyond the traditional treatment modalities, exploitation of RNA interference (RNAi) as an emerging approach has immense potential for the treatment of various gene-caused diseases including cancer. The last decade has witnessed enormous research and achievements focused on RNAi biotechnology. However, delivery of small interference RNA (siRNA) remains a key challenge in the development of clinical RNAi therapeutics. Indeed, functional nanomaterials play an important role in siRNA delivery, which could overcome a wide range of sequential physiological and biological obstacles. Nanomaterial-formulated siRNA systems have potential applications in protection of siRNA from degradation, improving the accumulation in the target tissues, enhancing the siRNA therapy and reducing the side effects. In this review, we explore and summarize the role of functional inorganic-organic hybrid systems involved in the siRNA therapeutic advancements. Additionally, we gather the surface engineering strategies of hybrid systems to optimize for siRNA delivery. Major progress in the field of inorganic-organic hybrid platforms including metallic/non-metallic cores modified with organic shells or further fabrication as the vectors for siRNA delivery is discussed to give credit to the interdisciplinary cooperation between chemistry, pharmacy, biology and medicine.

Original languageEnglish (US)
Pages (from-to)1969-1995
Number of pages27
JournalChemical Society Reviews
Volume47
Issue number6
DOIs
StatePublished - Mar 21 2018

ASJC Scopus subject areas

  • General Chemistry

Fingerprint

Dive into the research topics of 'Engineering functional inorganic-organic hybrid systems: Advances in siRNA therapeutics'. Together they form a unique fingerprint.

Cite this